Using a complete suite of complementary and integrated technologies, Igenica discovers targets expressed on patient tumors, selects antibodies generated in the context of the disease and can deploy them as unmodified, site-specific antibody-drug conjugates (ADCs). Igenica has built a rich and diverse pipeline of proprietary product candidates.  Learn More